Lupin Acquisition


'Lupin Acquisition' - 4 News Result(s)

  • Lupin, Gavis to Sell 2 Drugs for Deal Approval

    Lupin, Gavis to Sell 2 Drugs for Deal Approval

    Homegrown drug major Lupin and Gavis Pharmaceuticals LLC, which the Indian firm announced to acquire in an $850-million deal last year, have agreed to divest two generic drugs as part of the US Federal Trade Commission's (FTC) requirement to complete the transaction.

  • Lupin Looks to Revive US Growth With $880-Million GAVIS Deal

    Lupin Looks to Revive US Growth With $880-Million GAVIS Deal

    Lupin Ltd, India's third-largest drug maker by sales, is buying US peer GAVIS Pharmaceuticals LLC for $880 million (Rs 5,588 crore at $1 = Rs 63.5) in its largest ever acquisition, seeking to revive its flagging growth in the United States, its largest market.

  • Lupin Plans to Beef Up Branded Portfolio Through Alliances in FY16

    Lupin Plans to Beef Up Branded Portfolio Through Alliances in FY16

    Pharmaceuticals major Lupin is looking at strengthening its branded portfolio by creating alliances and eyeing strategic brand acquisitions in US markets in 2015-16.

  • Scouting For Acquisitions in India: Lupin

    Scouting For Acquisitions in India: Lupin

    The Mumbai-based firm, which is the fifth largest generic player in the US market, has so far stayed away from inorganic growth in India where it clocked revenues of Rs 2,479 crore in the previous fiscal.

'Lupin Acquisition' - 4 News Result(s)

  • Lupin, Gavis to Sell 2 Drugs for Deal Approval

    Lupin, Gavis to Sell 2 Drugs for Deal Approval

    Homegrown drug major Lupin and Gavis Pharmaceuticals LLC, which the Indian firm announced to acquire in an $850-million deal last year, have agreed to divest two generic drugs as part of the US Federal Trade Commission's (FTC) requirement to complete the transaction.

  • Lupin Looks to Revive US Growth With $880-Million GAVIS Deal

    Lupin Looks to Revive US Growth With $880-Million GAVIS Deal

    Lupin Ltd, India's third-largest drug maker by sales, is buying US peer GAVIS Pharmaceuticals LLC for $880 million (Rs 5,588 crore at $1 = Rs 63.5) in its largest ever acquisition, seeking to revive its flagging growth in the United States, its largest market.

  • Lupin Plans to Beef Up Branded Portfolio Through Alliances in FY16

    Lupin Plans to Beef Up Branded Portfolio Through Alliances in FY16

    Pharmaceuticals major Lupin is looking at strengthening its branded portfolio by creating alliances and eyeing strategic brand acquisitions in US markets in 2015-16.

  • Scouting For Acquisitions in India: Lupin

    Scouting For Acquisitions in India: Lupin

    The Mumbai-based firm, which is the fifth largest generic player in the US market, has so far stayed away from inorganic growth in India where it clocked revenues of Rs 2,479 crore in the previous fiscal.

Your search did not match any documents
A few suggestions
  • Make sure all words are spelled correctly
  • Try different keywords
  • Try more general keywords
Check the NDTV Archives:https://archives.ndtv.com

................................ Advertisement ................................

................................ Advertisement ................................

Listen to the latest songs, only on JioSaavn.com